Related Experiment Video
Updated: Jul 25, 2025

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
Published on: January 10, 2025
Effect of Mitotane on Male Gonadal Function
Federica Innocenti1, Sara Di Persio1, Marilena Taggi1
1Department of Anatomy, Histology, Forensic Medicine and Orthopedic, Section of Histology, Sapienza University of Rome, 00185 Rome, Italy.
Background:
Clinical evidence has shown frequent hypogonadism following mitotane (MTT) treatment in male patients with adrenocortical carcinoma. This study aimed to evaluate the impact of MTT on male gonadal function.
Methods:
Morphological analysis of testes and testosterone assays were performed on adult CD1 MTT-treated and untreated mice. The expression of key genes involved in interstitial and tubular compartments was studied by real-time PCR. Moreover, quantitative and qualitative analysis of spermatozoa was performed.
Results:
Several degrees of damage to the testes and a significant testosterone reduction in MTT-treated mice were observed. A significant decline in 3βHsd1 and Insl3 mRNA expression in the interstitial compartment confirmed an impairment of androgen production. Fsh-R mRNA expression was unaffected by MTT, proving that Sertoli cells are not the drug's primary target. Sperm concentrations were significantly lower in MTT-treated animals. Moreover, the drug caused a significant increase in the percentage of spermatozoa with abnormal chromatin structures.
Conclusion:
MTT negatively affects the male reproductive system, including changes in the morphology of testicular tissue and reductions in sperm concentration and quality.
Insights
Mitotane (MTT) treatment for adrenocortical carcinoma causes testicular damage and reduces testosterone levels in male mice. This impacts sperm count and quality, affecting male reproductive health.
Area of Science:
- Endocrinology
- Reproductive Biology
- Toxicology
Background:
- Adrenocortical carcinoma treatment with mitotane (MTT) is associated with hypogonadism in male patients.
- The precise impact of MTT on male gonadal function requires further investigation.
Purpose of the Study:
- To evaluate the effects of mitotane (MTT) on male reproductive system function in a preclinical model.
- To assess testicular morphology, hormone levels, gene expression, and sperm parameters following MTT exposure.
Main Methods:
- Adult male CD1 mice were treated with MTT or a placebo.
- Testicular histology, serum testosterone levels, key gene expression (real-time PCR), and sperm analysis were performed.
- Quantitative and qualitative sperm parameters, including chromatin structure, were assessed.
Main Results:
- MTT induced testicular damage and significantly reduced testosterone levels.
- Impaired androgen production was indicated by decreased 3βHsd1 and Insl3 mRNA expression.
- Sperm concentration decreased, and the percentage of spermatozoa with abnormal chromatin structures increased significantly.
Conclusions:
- Mitotane (MTT) adversely affects the male reproductive system.
- MTT treatment leads to testicular tissue damage, reduced sperm concentration, and impaired sperm quality.
Related Concept Videos
Infertility in Males
Spermatogenesis
Gonadal and Placental Hormones
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair...
Menopause
Meiosis vs. Mitosis
Before the start of mitosis and meiosis I, the cell synthesizes DNA, resulting in two homologous copies of each chromosome. DNA synthesis is...
Testosterone: Functions and Regulation

